Lucid Diagnostics to Have a Productive Year, Says Cantor Fitzgerald By Investing.com
© Reuters. By Sam Boughedda Investing.com — Lucid Diagnostics Inc (NASDAQ:) shares rose 5% on Tuesday after Cantor Fitzgerald analyst Ross Osborn reiterated an overweight rating and $12 price target. Osborn said the company “will […]
